Related Experiment Videos
MICE: a new active combination for non-small cell lung cancer
G Arcangeli1, A Zaniboni, S Milano
1Servizio di Oncologia, Spedali Civili, Brescia, Italy.
European Journal of Cancer (Oxford, England : 1990)
|January 1, 1993
Summary
The MICE regimen, combining mitomycin-C, ifosfamide, cisplatin, and vindesine, showed a 57% partial remission rate in stage IV non-small cell lung cancer patients. This chemotherapy combination warrants further study for cancer palliation and neoadjuvant treatment.
Area of Science:
- Medical Oncology
- Clinical Pharmacology
Background:
- Non-small cell lung cancer (NSCLC) remains a leading cause of cancer-related mortality.
- Effective treatment strategies for advanced (stage III/IV) NSCLC are crucial for improving patient outcomes.
Purpose of the Study:
- To evaluate the efficacy and toxicity of the MICE chemotherapy regimen in patients with stage III/IV non-small cell lung cancer.
- To assess the response rate, time to disease progression, and survival in this patient cohort.
Main Methods:
- A total of 38 patients with stage III/IV NSCLC received the MICE regimen (mitomycin-C, ifosfamide, cisplatin, vindesine) intravenously every 3 weeks.
- Response rates, including partial remission (PR), were assessed.
- Toxicity profiles, including leucopenia, neutropenic fever, and anemia, were documented.
Main Results:
- Among 26 stage IV NSCLC patients, 15 achieved a partial remission, yielding a response rate of 57% (95% CI: 38-76).
- Median time to disease progression was 4.9 months, and median survival was 7.1 months.
- In stage IIIA NSCLC, 6 out of 7 patients achieved PR, with 5 undergoing radical surgery and 2 achieving complete remission.
Conclusions:
- The MICE regimen demonstrates promising activity in advanced non-small cell lung cancer, with a notable response rate and manageable toxicity.
- Further investigation of the MICE regimen is warranted for both palliative care and neoadjuvant treatment settings in NSCLC.